Clinical Trial Update: GEN-001 Plus Pembrolizumab for Patients With Advanced Refractory Biliary Tract Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating GEN-001 in combination with pembrolizumab for advanced biliary tract cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer

Drugs mentioned

• GEN-001
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Genome & Company | Conditions: Biliary Tract Cancer | Phase 2 | Status: TERMINATED